CSC's Domain Security Report 2026 Finds Unicorns Outpace Global 2000 Companies in Five out of Eight Domain Security Categories
20.1.2026 15:00:00 CET | Business Wire | Press Release
CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and domain name system (DNS) threats, today released its Domain Security Report 2026, which found that unicorns—privately owned start-ups or relatively new innovative companies with a valuation of over $1 billion—have a higher score than the Forbes Global 2000 companies in five out of eight domain security capabilities. While significantly more unicorns sit in the middle range for domain risk scores compared to the Global 2000, they tend to lack more advanced security protocols, such as registry lock and DNS redundancy.
CSC’s Domain Security Report 2026 analyzes the security posture of the Global 2000 based on their adoption of key domain security features like type of registrar, registry lock, certificate authority authorization (CAA) records, DNS redundancy, DNS security extensions (DNSSEC), sender policy framework (SPF), DomainKeys Identified Mail (DKIM), and domain-based message authentication, reporting, and conformance (DMARC). Now in its sixth year, the annual report also compared the domain security practices of the Global 2000 with those of the world’s top 100 unicorns to determine if newer start-ups are more attuned to domain security risks and have the ability to implement the right practices to address such risks.
The majority of the top 100 unicorns are IT companies, with many in the artificial intelligence (AI) industry. Teams managing the domain names for the unicorns are likely IT professionals with good knowledge of the security protocols available within DNS. This could explain why they lead in many of the security features that are managed through DNS records, yet only 1% employ DNS redundancy and close to 90% use a single cloud infrastructure. The adoption of advanced domain security measures could be low due to higher use of consumer-grade registrars, which often do not prioritize or even offer certain domain security measures.
“Domain names, DNS, and brand trust are fundamental to our online presence. Long-overlooked dependencies will compound cyber risks as new AI and IT stacks emerge,” states Vincent D’Angelo, senior director at CSC. “It’s encouraging to see unicorns adopting strong domain security practices early, yet much work remains. As these new tech platforms scale, continued prioritization of domain security will be essential to reducing cybercrime, strengthening trust and safety, and lowering systemic risk across customer and partner supply chains.”
Additional key insights from CSC’s research on the Global 2000 include:
- The semiconductor and banking industries show the most significant rise in overall domain security scores over the past year, increasing their rankings by five places each. The rapid growth in security posture for the two industries could be in response to the parallel growth in artificial intelligence and FinTech technology over the past year, coupled with more stringent cybersecurity demands from regional governments and agencies.
- The disparity in registry lock adoption between Global 2000 companies using enterprise-class vs. consumer-grade registrar is more than six times. Registry locks offer one of the strongest defenses against domain hijacking, but due to the resources required to support this service, most consumer-grade registrars are unable to offer it.
- 88% of the registered web domains that resemble Global 2000 brands (homoglyphs) are owned by third parties and do not belong to the brand—up 8% since last year’s report. Homoglyphs are one of the most egregious attack methods used by threat actors to exploit trusted brands through fraudulent websites, false advertisements, phishing emails and other malicious content meant to trick consumers.
- DMARC rose quickly from 39% in 2020 to 80% in 2025—the fastest growth among domain security measures. The increase in volume and complexity of phishing attacks, along with the European Union’s Network and Information Security 2 (NIS2) directive coming into effect in October 2024, could be driving factors for this accelerated adoption.
The domain landscape faces rapid evolution as cyber threat actors become more efficient, regulations like NIS2 pay greater attention to domain security, and life cycles for Secure Sockets Layer (SSL) and Transport Layer Security (TLS) digital certificates will begin to shrink in 2026, significantly impacting current domain management policies for many organizations. CSC continues to publish its annual Domain Security Report to keep organizations informed on the challenges that could disrupt their business operations within this shifting landscape, along with the domain security practices that can help them stay ahead of emerging risks.
To learn more about CSC’s approach to domain security, visit cscdbs.com. Download the Domain Security Report 2026 now at cscdbs.com/en/resources/domain-security-report-2026/.
About CSC
CSC is the trusted security and threat intelligence provider of choice for the Forbes Global 2000 and the 100 Best Global Brands (Interbrand®) with focus areas in domain security and management, along with digital brand and fraud protection. As global companies make significant investments in their security posture, our DomainSec℠ platform can help them understand cybersecurity oversights that exist and help them secure their online digital assets and brands. By leveraging CSC’s proprietary technology, companies can solidify their security posture to protect against cyber threat vectors targeting their online assets and brand reputation, helping them avoid devastating revenue loss. CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—with a multidimensional view of various threats outside the firewall targeting specific domains. Fraud protection services that combat phishing in the early stages of attack round out our solutions. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260120646416/en/
Contacts
Joyson Cherian
W2 Communications
CSC@w2comm.com
CSC News Room -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cscglobal.
com%2Fglobal%2Fweb%2Fcsc%2Fpress-releases.html&esheet=54398591&newsitemid=202601
20646416&lan=en-US&anchor=CSC+News+Room&index=7&md5=420e0ee34fb5f90cefba6b43cbcc
4845
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom